OBJECTIVE: Increased systemic inflammation is associated with stress-related psychopathology. Specifically, levels of the proinflammatory marker C-reactive protein (CRP) are elevated in individuals with posttraumatic stress disorder (PTSD). Furthermore, single-nucleotide polymorphisms (SNPs) in the CRP gene are associated with CRP level, risk for cardiovascular disease, and obesity. The authors examined whether polymorphisms within the CRP gene and increased CRP levels are associated with PTSD symptoms and fear physiology in a civilian population with high levels of trauma. METHOD: Cross-sectional data and DNA samples were collected from 2,698 individuals recruited from an inner-city public hospital that serves a primarily African American, low-socioeconomic-status population. A subgroup of 187 participants participated in further interviews, testing, and physiological measures; of these, 135 were assessed using the fear-potentiated startle paradigm to assess fear-related phenotypes of PTSD. RESULTS: One SNP within the CRP gene, rs1130864, was significantly associated with increased PTSD symptoms (N=2,692), including "being overly alert" as the most significant individual symptom (N=2,698). Additionally, CRP genotype was associated with the odds of PTSD diagnosis (N=2,692). This SNP was also associated with increased CRP level (N=137), and high CRP levels (>3 mg/L) were positively associated with PTSD symptoms (N=187) and fear-potentiated startle to a safety signal (N=135). CONCLUSIONS: Together, these data indicate that genetic variability in the CRP gene is associated with serum CRP level and PTSD symptom severity, including that of hyperarousal symptoms. Elevated CRP levels were also associated with exacerbated fear-related psychophysiology and PTSD symptom ratings and diagnosis. These findings suggest a potential mechanism by which an increased proinflammatory state may lead to heightened PTSD symptoms.
OBJECTIVE: Increased systemic inflammation is associated with stress-related psychopathology. Specifically, levels of the proinflammatory marker C-reactive protein (CRP) are elevated in individuals with posttraumatic stress disorder (PTSD). Furthermore, single-nucleotide polymorphisms (SNPs) in the CRP gene are associated with CRP level, risk for cardiovascular disease, and obesity. The authors examined whether polymorphisms within the CRP gene and increased CRP levels are associated with PTSD symptoms and fear physiology in a civilian population with high levels of trauma. METHOD: Cross-sectional data and DNA samples were collected from 2,698 individuals recruited from an inner-city public hospital that serves a primarily African American, low-socioeconomic-status population. A subgroup of 187 participants participated in further interviews, testing, and physiological measures; of these, 135 were assessed using the fear-potentiated startle paradigm to assess fear-related phenotypes of PTSD. RESULTS: One SNP within the CRP gene, rs1130864, was significantly associated with increased PTSD symptoms (N=2,692), including "being overly alert" as the most significant individual symptom (N=2,698). Additionally, CRP genotype was associated with the odds of PTSD diagnosis (N=2,692). This SNP was also associated with increased CRP level (N=137), and high CRP levels (>3 mg/L) were positively associated with PTSD symptoms (N=187) and fear-potentiated startle to a safety signal (N=135). CONCLUSIONS: Together, these data indicate that genetic variability in the CRP gene is associated with serum CRP level and PTSD symptom severity, including that of hyperarousal symptoms. Elevated CRP levels were also associated with exacerbated fear-related psychophysiology and PTSD symptom ratings and diagnosis. These findings suggest a potential mechanism by which an increased proinflammatory state may lead to heightened PTSD symptoms.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: David Furman; Boris P Hejblum; Noah Simon; Vladimir Jojic; Cornelia L Dekker; Rodolphe Thiébaut; Robert J Tibshirani; Mark M Davis Journal: Proc Natl Acad Sci U S A Date: 2013-12-23 Impact factor: 11.205
Authors: J S Pankow; A R Folsom; M Cushman; I B Borecki; P N Hopkins; J H Eckfeldt; R P Tracy Journal: Atherosclerosis Date: 2001-02-15 Impact factor: 5.162
Authors: Sarah J Spann; Charles F Gillespie; Jennifer S Davis; Angelo Brown; Ann Schwartz; Aliza Wingo; Leah Habib; Kerry J Ressler Journal: Gen Hosp Psychiatry Date: 2013-10-19 Impact factor: 3.238
Authors: Satish A Eraly; Caroline M Nievergelt; Adam X Maihofer; Donald A Barkauskas; Nilima Biswas; Agorastos Agorastos; Daniel T O'Connor; Dewleen G Baker Journal: JAMA Psychiatry Date: 2014-04 Impact factor: 21.596
Authors: Rebekah G Bradley; Elisabeth B Binder; Michael P Epstein; Yilang Tang; Hemu P Nair; Wei Liu; Charles F Gillespie; Tiina Berg; Mark Evces; D Jeffrey Newport; Zachary N Stowe; Christine M Heim; Charles B Nemeroff; Ann Schwartz; Joseph F Cubells; Kerry J Ressler Journal: Arch Gen Psychiatry Date: 2008-02
Authors: Nikolaos P Daskalakis; Chuda M Rijal; Christopher King; Laura M Huckins; Kerry J Ressler Journal: Curr Psychiatry Rep Date: 2018-04-05 Impact factor: 5.285
Authors: Omid G Sani; Yuxiao Yang; Morgan B Lee; Heather E Dawes; Edward F Chang; Maryam M Shanechi Journal: Nat Biotechnol Date: 2018-09-10 Impact factor: 54.908
Authors: M W Miller; H Maniates; E J Wolf; M W Logue; S A Schichman; A Stone; W Milberg; R McGlinchey Journal: Brain Behav Immun Date: 2017-09-01 Impact factor: 7.217
Authors: Jeanne E Savage; Chelsea Sawyers; Roxann Roberson-Nay; John M Hettema Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-05-19 Impact factor: 3.568